A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes
Phase 3 data with longer follow-up will clarify the long-term glycemic profile
Many compounding providers add these supplements to their formulations
Insulin helps lower blood sugar levels, and when used in combination with Semaglutide, it can lead to excessive insulin production and a drop in blood sugar levels
Retrieved September 22, 2025
It belongs to the GLP-1 receptor agonist class of drugs, which includes Mounjaro, Rybelsus and Wegovy